Nchi: Uholanzi
Lugha: Kiholanzi
Chanzo: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
NATRIUMIBANDRONAAT 1-WATER 1,125 mg/ml SAMENSTELLING overeenkomend met ; IBANDRONINEZUUR 1 mg/l
Teva Nederland B.V. Swensweg 5 2031 GA HAARLEM
M05BA06
NATRIUMIBANDRONAAT 1-WATER 1,125 mg/ml SAMENSTELLING overeenkomend met ; IBANDRONINEZUUR 1 mg/l
Oplossing voor injectie
AZIJNZUUR (E 260), GECONCENTREERD ; NATRIUMACETAAT 3-WATER (E 262) ; NATRIUMCHLORIDE ; NATRIUMHYDROXIDE (E 524) ; WATER VOOR INJECTIE,
Intraveneus gebruik
Ibandronic Acid
Hulpstoffen: AZIJNZUUR (E 260), GECONCENTREERD; NATRIUMACETAAT 3-WATER (E 262); NATRIUMCHLORIDE; NATRIUMHYDROXIDE (E 524); WATER VOOR INJECTIE;
1900-01-01
Ibandronic acid, NL/H/2362/003, 05.09.22 1 rvg 109743 EU PIL IA-021 met NL info-clean BIJSLUITER: INFORMATIE VOOR DE GEBRUIKER IBANDRONINEZUUR TEVA 3 MG, OPLOSSING VOOR INJECTIE IN VOORGEVULDE SPUIT ibandronic acid READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What <[Ibandronic acid]> is and what it is used for 2. What you need to know before you receive <[Ibandronic acid]> 3. How to receive < Ibandronic acid 3 mg solution for injection> 4. Possible side effects 5. How to store <[Ibandronic acid]> 6. Contents of the pack and other information 1. WHAT <[IBANDRONIC ACID]> IS AND WHAT IT IS USED FOR Ibandronic acid belongs to a group of medicines called BISPHOSPHONATES . It contains the active substance ibandronic acid. Ibandronic acid may reverse bone loss by stopping more loss of bone and increasing bone mass in most women who take it, even though they won’t be able to see or feel a difference. Ibandronic acid may help lower the chances of breaking bones (fractures). This reduction in fractures was shown for the spine but not for the hip. IBANDRONIC ACID IS PRESCRIBED TO YOU TO TREAT POSTMENOPAUSAL OSTEOPOROSIS BECAUSE YOU HAVE AN INCREASED RISK OF FRACTURES. Osteoporosis is a thinning and weakening of the bones, which is common in women after the menopause. At the menopause, a woman’s ovaries stop producing the female hormone, oestrogen, which helps to keep her skeleton healthy. The earlier a woman reaches the menopause, the greater her risk of fractures in osteoporosis. Other things that can increase the risk of fractures include: − not enough calcium and vitamin D in the diet − smoking cigarettes, or drinking too much Soma hati kamili
Ibandronic acid, NL/H/2362/003, 05.09.22 1 rvg 109743 EU SPC IA-021 met NL info-clean 1. NAAM VAN HET GENEESMIDDEL Ibandroninezuur Teva 3 mg, oplossing voor injectie in voorgevulde spuit 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One pre-filled syringe of 3 ml solution for injection contains 3 mg ibandronic acid (as 3.375 mg ibandronic acid, monosodium salt, monohydrate). The concentration of ibandronic acid in the solution for injection is 1 mg per ml. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection in pre-filled syringe. Clear, colourless solution. The pH of the solution is 4.9 – 5.5. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1). A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Patients treated with ibandronic acid should be given the package leaflet and the patient reminder card. Posology The recommended dose of ibandronic acid is 3 mg, administered as an intravenous injection over 15 - 30 seconds, every three months. Patients must receive supplemental calcium and vitamin D (see section 4.4 and section 4.5). If a dose is missed, the injection should be administered as soon as convenient. Thereafter, injections should be scheduled every 3 months from the date of the last injection. The optimal duration of bisphosphonate treatment for osteoporosis has not been established. The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of ibandronic acid on an individual patient basis, particularly after 5 or more years of use. _ _ _Special populations _ _Patients with renal impairment _ Ibandronic acid injection is not recommended for use in patients who have a serum creatinine above 200 μmol/l (2.3 mg/dl) or who have a creatinine clearance (measured or estimated) below 30 ml/min, because Soma hati kamili